BACKGROUND: A minority of patients with adult acute lymphoblastic leukemia who relapse are rescued. The aim of this population-based study was to assess the results of reinduction treatment and allogeneic stem cell transplantation in patients in second complete remission. DESIGN AND METHODS: Between 2003-2007, 76 adults (<66 years) with relapsed acute lymphoblastic leukemia (Burkitt's leukemia excluded) were prospectively reported to The Swedish Adult Acute Leukemia Registry and later evaluated. RESULTS: Reinduction with: (i) mitoxantrone, etoposide, and cytarabine (MEA); (ii) fludarabine, cytarabine, pegylated-asparaginase plus granulocyte colony-stimulating factor (FLAG-Asp); and (iii) cytarabine, betamethasone, cyclophosphamide, daunorubicin, and vincristine (ABCDV) resulted in complete remission in 6/9 (67%), 10/16 (63%) and 9/21 (43%) of the patients, respectively. Allogeneic stem cell transplantation was performed during second complete remission in 29 patients. Multivariate analysis regarding overall survival after relapse revealed that age over 35 years at diagnosis and relapse within 18 months were negative prognostic factors. Overall survival rates at 3 and 5 years were 22% (95% CI: 13-32) and 15% (95% CI: 7-24). Of 19 patients less than 35 years at diagnosis who underwent allogeneic stem cell transplantation in second remission, ten (53%) are still alive at a median of 5.5 years (range, 4.2-8.3) after relapse, whereas all patients over 35 years old at diagnosis have died. CONCLUSIONS: Allogeneic stem cell transplantation remains the treatment of choice for young adults with relapsed acute lymphoblastic leukemia. Both (i) mitoxantrone, etoposide, and cytarabine and (ii) fludarabine, cytarabine, pegylated-asparaginase plus granulocyte colony-stimulating factor seem effective as reinduction treatments and should be further evaluated. New salvage strategies are needed, especially for patients over 35 years old at diagnosis.
BACKGROUND: A minority of patients with adult acute lymphoblastic leukemia who relapse are rescued. The aim of this population-based study was to assess the results of reinduction treatment and allogeneic stem cell transplantation in patients in second complete remission. DESIGN AND METHODS: Between 2003-2007, 76 adults (<66 years) with relapsed acute lymphoblastic leukemia (Burkitt's leukemia excluded) were prospectively reported to The Swedish Adult Acute Leukemia Registry and later evaluated. RESULTS: Reinduction with: (i) mitoxantrone, etoposide, and cytarabine (MEA); (ii) fludarabine, cytarabine, pegylated-asparaginase plus granulocyte colony-stimulating factor (FLAG-Asp); and (iii) cytarabine, betamethasone, cyclophosphamide, daunorubicin, and vincristine (ABCDV) resulted in complete remission in 6/9 (67%), 10/16 (63%) and 9/21 (43%) of the patients, respectively. Allogeneic stem cell transplantation was performed during second complete remission in 29 patients. Multivariate analysis regarding overall survival after relapse revealed that age over 35 years at diagnosis and relapse within 18 months were negative prognostic factors. Overall survival rates at 3 and 5 years were 22% (95% CI: 13-32) and 15% (95% CI: 7-24). Of 19 patients less than 35 years at diagnosis who underwent allogeneic stem cell transplantation in second remission, ten (53%) are still alive at a median of 5.5 years (range, 4.2-8.3) after relapse, whereas all patients over 35 years old at diagnosis have died. CONCLUSIONS: Allogeneic stem cell transplantation remains the treatment of choice for young adults with relapsed acute lymphoblastic leukemia. Both (i) mitoxantrone, etoposide, and cytarabine and (ii) fludarabine, cytarabine, pegylated-asparaginase plus granulocyte colony-stimulating factor seem effective as reinduction treatments and should be further evaluated. New salvage strategies are needed, especially for patients over 35 years old at diagnosis.
Authors: H M Kantarjian; S O'Brien; T L Smith; J Cortes; F J Giles; M Beran; S Pierce; Y Huh; M Andreeff; C Koller; C S Ha; M J Keating; S Murphy; E J Freireich Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: Jacob M Rowe; Georgina Buck; Alan K Burnett; Raj Chopra; Peter H Wiernik; Susan M Richards; Hillard M Lazarus; Ian M Franklin; Mark R Litzow; Niculae Ciobanu; H Grant Prentice; Jill Durrant; Martin S Tallman; Anthony H Goldstone Journal: Blood Date: 2005-08-16 Impact factor: 22.113
Authors: Andrea Camera; Luciana Annino; Federico Chiurazzi; Paola Fazi; Nicola Cascavilla; Francesco Fabbiano; Filippo Marmont; Francesco Di Raimondo; Anna Recchia; Marco Vignetti; Bruno Rotoli; Franco Mandelli Journal: Haematologica Date: 2004-02 Impact factor: 9.941
Authors: D Hoelzer; W D Ludwig; E Thiel; W Gassmann; H Löffler; C Fonatsch; H Rieder; G Heil; B Heinze; R Arnold; D Hossfeld; T Büchner; P Koch; M Freund; W Hiddemann; G Maschmeyer; A Heyll; C Aul; T Faak; R Kuse; T H Ittel; M Gramatzki; H Diedrich; K Kolbe; H G Fuhr; K Fischer; C Schadeck-Gressel; A Weiss; I Strohscheer; B Metzner; U Fabry; N Gökbuget; B Völkers; D Messerer; K Uberla Journal: Blood Date: 1996-01-15 Impact factor: 22.113
Authors: E Tavernier; J-M Boiron; F Huguet; K Bradstock; N Vey; T Kovacsovics; A Delannoy; N Fegueux; P Fenaux; A Stamatoullas; O Tournilhac; A Buzyn; O Reman; C Charrin; C Boucheix; J Gabert; V Lhéritier; J-P Vernant; H Dombret; X Thomas Journal: Leukemia Date: 2007-07-05 Impact factor: 11.528
Authors: Anthony H Goldstone; Susan M Richards; Hillard M Lazarus; Martin S Tallman; Georgina Buck; Adele K Fielding; Alan K Burnett; Raj Chopra; Peter H Wiernik; Letizia Foroni; Elisabeth Paietta; Mark R Litzow; David I Marks; Jill Durrant; Andrew McMillan; Ian M Franklin; Selina Luger; Niculae Ciobanu; Jacob M Rowe Journal: Blood Date: 2007-11-29 Impact factor: 22.113
Authors: Adele K Fielding; Susan M Richards; Rajesh Chopra; Hillard M Lazarus; Mark R Litzow; Georgina Buck; I Jill Durrant; Selina M Luger; David I Marks; Ian M Franklin; Andrew K McMillan; Martin S Tallman; Jacob M Rowe; Anthony H Goldstone Journal: Blood Date: 2006-10-10 Impact factor: 22.113
Authors: Partow Kebriaei; Kaci Wilhelm; Farhad Ravandi; Mark Brandt; Marcos de Lima; Stefan Ciurea; Laura Worth; Susan O'Brien; Deborah Thomas; Richard E Champlin; Hagop Kantarjian Journal: Clin Lymphoma Myeloma Leuk Date: 2013-01-10
Authors: Kyung Nam Koh; Ho Joon Im; Hyery Kim; Hyoung Jin Kang; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn; Ji Won Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Young Tak Lim; Jun Eun Park; Byung Kiu Park; Hyeon Jin Park; Jong Jin Seo Journal: J Korean Med Sci Date: 2017-04 Impact factor: 2.153
Authors: Emma Lennmyr; Karin Karlsson; Lucia Ahlberg; Hege Garelius; Erik Hulegårdh; Antonio S Izarra; Joel Joelsson; Piotr Kozlowski; Andreea Moicean; Beata Tomaszewska-Toporska; Anna Lübking; Helene Hallböök Journal: Eur J Haematol Date: 2019-06-06 Impact factor: 2.997